Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789

Phase 1

Completed

• Conditions: Alzheimer Disease; Healthy Subjects
• Interventions: Other: placebo; Drug: NSA-789

• Registration Number: NCT00795730
• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Brief Summary

This is a multiple dose study of NSA-789, the purpose of which is to assess the safety and tolerability in healthy subjects and subjects with Alzheimer's Disease

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2008-11-20
• Study First Submitted QC: 2008-11-20
• Study First Posted: 2008-11-21
• Study Start: 2009-01
• Primary Completion: 2009-05
• Study Completion: 2009-05
• Status Verified: 2021-08
• Last Update Submitted: 2021-08-17
• Last Update Posted: 2021-08-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
placebo	placebo	-
NSA-789	NSA-789	-

Primary Outcome Measures

Name	Time	Method
Adverse event monitoring as specific tests that will be done to monitor safety (ECGs, certain laboratory tests, vital signs) and tolerability	6 months

Secondary Outcome Measures

Name	Time	Method
Pharmacokinetic and pharmcodynamic parameters	6 months